1 / 54

WHO's Immunization Policy Framework: Is it achieving its goals? :

WHO's Immunization Policy Framework: Is it achieving its goals? :. Professor Helen Rees Chairperson, WHO’s Strategic Advisory Group of Experts (SAGE) Wits Reproductive Health and HIV Institute, South Africa Global Vaccines 202X, Philadelphia, May 2011.

Download Presentation

WHO's Immunization Policy Framework: Is it achieving its goals? :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. WHO's Immunization Policy Framework: Is it achieving its goals? : Professor Helen Rees Chairperson, WHO’s Strategic Advisory Group of Experts (SAGE) Wits Reproductive Health and HIV Institute, South Africa Global Vaccines 202X, Philadelphia, May 2011

  2. Civil Society and Immunization Policy Who do we trust?

  3. About the World and Vaccines Lets take a lesson from HIV • Grassroots activism in developing and developed worlds • Political pressure • Global Pharma partnerships about costs • Mobilising resources • Global impact being internationally watched The Vaccine world • Lacks grassroots activism • Programmes been mostly top down, taken for granted • Enthusiasts work with each other within the vaccine world • Pharma a major player but more transparency about costing required • Threatened by vaccine hesitancy and weak health services

  4. About WHO • WHO is the directing and coordinating authority for health within the United Nations system. In the 21st century, health is a shared responsibility, involving equitable access to essential care and collective defence against transnational threats. • It is responsible for providing leadership on global health matters • Shaping the health research agenda • Setting norms and standards • Articulating evidence-based policy options • Providing technical support to countries • Monitoring and assessing health trends.

  5. WHO’s challenge There is no substitute for the WHO, with its progressive constitution and global legitimacy. It is not likely that the same powers would be granted to an international organization if it were created today. Consequently, while remaining true to its normative and bold vision of health for all, the WHO must adapt to a new political climate, demonstrate global leadership, and deliver results.

  6. A critical appraisal of WHO’s immunization policy framework Can we trust them? I think so, they go to lots of meetings…

  7. Immunization Policy Advisory Framework • Safety • Standards • Practice • Burden assessment/ • modelling Strategic Advisory Group of Experts (SAGE) • Global policy recommendations & strategies • Support regional/national challenges Other WHO Technical Advisory Committees • Regional policies & strategies • Identify & set regional priorities • Monitor regional progress Regional Technical Advisory Group • National Policies & Strategies • Prioritize problems & define optimal solutions • Implement national programme & monitor impact Countries National Technical Advisory Group on Immunization

  8. Strategic Advisory Group of Experts (SAGE) • Principal advisory group to WHO for vaccines and immunization: from research to delivery of immunization and linkages with other health interventions - all vaccines, all ages • Reports directly to WHO’s Director General and involves all relevant WHO departments • Restructured in 2005 in context of Global Immunization Vision and Strategy

  9. Strategic Advisory Group of Experts (SAGE) • Membership -15 members • Individual capacity and broad range of expertise • Balance of professional affiliation, area of interest, geographic representation • Declarations of interest • Appointed by WHO DG upon recommendation of external selection panel • Rotation • Reappointment subject to participation/contribution and review by selection panel • Public call for nominations

  10. Strategic Advisory Group of Experts (SAGE) • Meetings and operational procedures • Two meetings a year (April and Nov) • Two preparatory teleconferences for each meeting • Only plenary sessions – transparent process • Extensive representation from keypartner organizations • Experts invited as needed • Evidence-based • Background documents web and Yellow Book • Tracking sheet for follow-up on implementation of recommendations • Working groups • Agenda setting • Strong links with Regional Technical Advisory Groups • Report and communications http://www.who.int/immunization/sage/en/index.html

  11. SAGE working groups • Establishment and ToRs decided by WHO and SAGE members • Composition • Public call for nominations • At least two SAGE members & additional experts • Declaration of interests • To review evidence and address specific issues in great depth and prepare for fruitful discussions at SAGE when issue is complex • Not allowed to make decisions or speak on behalf of SAGE • Time limited • Currently 8 active working groups

  12. SAGE Agenda-setting process • Agenda developed in consultation with SAGE members, other HQ departments, regional offices, stakeholders and countries • Two year horizon • Due diligence but need for sufficient evidence and preparation including working groups, other technical advisory groups or other committees • Expected output • For DECISION, DISCUSSION, or INFORMATION • Search engine for topics previously discussed • http://whqpasteur.who.int:8081/sage_search_php/index.php

  13. Issues taken into consideration by SAGE in the development of recommendations • Disease epidemiology • Disease burden including age specific mortality, morbidity, and societal impact; specific risk groups; epidemic potential; disease occurrence over time; serogroup or serotype distribution; and changes in epidemiology over time • Clinical characteristics • Clinical management of disease, disease severity, primary/secondary/tertiary care implications, long term complications of disease and medical requirements • Evidence-based recommendations based on GRADing system

  14. Issues taken into consideration by SAGE in the development of recommendations • Vaccine and immunization characteristics • efficacy, effectiveness and population impact of vaccine; vaccine safety; indirect protective effects or safety concerns; cold chain and logistics concerns; vaccine availability; vaccine schedules; schedules social and programmatic acceptability, ability to monitor program impact • Economic considerations • disease, vaccine and vaccine delivery costs, potential for vaccine price reduction, vaccine cost and cost-effectiveness of immunization programmes, and affordability of immunization • Health system opportunities and existence of and interaction with other existing intervention and control strategies • Social impact • Legal considerations • Ethical considerations

  15. Is SAGE delivering on Access, Equity & Ethics? • Transparent, public appointment process • Declaration of interests • Regional representation on SAGE & Regional viewpoints • Open plenaries & transparent decision making • Public access to decisions • Best evidence-based recommendations • Impact: • Usefulness • Communication and access • Credibility • Guided by equity, ethics and access

  16. SAGE Agenda: April 2011 meeting SPECIFIC TOPICS Pandemic and seasonal influenza vaccines Tick-borne encephalitis Meningococcal meningitis vaccines Rubella vaccination immunization schedules Polio eradication Update of evidence-based review process and GRADing of quality of scientific evidence Cholera vaccine RUNNING ITEMS Global progress & implementation of recommendations Regional reports Reports from other ImmunizationAdvisory Committees - Advisory Committee of the Initiative for Vaccine Research - Global Advisory Committee on Vaccines Safety Report from the GAVI Alliance

  17. Access, Equity, Ethics in new SAGE agenda items

  18. Immunization Policy Advisory Framework • Safety • Standards • Practice • Burden assessment/ • modelling Strategic Advisory Group of Experts (SAGE) • Global policy recommendations & strategies • Support regional/national challenges Other WHO Technical Advisory Committees • Regional policies & strategies • Identify & set regional priorities • Monitor regional progress Regional Technical Advisory Group • National Policies & Strategies • Prioritize problems & define optimal solutions • Implement national programme & monitor impact Countries National Technical Advisory Group on Immunization

  19. Regional Technical Advisory Group Regional policies & strategies Identify & set regional priorities Monitor regional progress Have a lot of autonomy • Critically important to adapt SAGE recommendations • Depends on high calibre staff and TAG appointees • Depends on good understanding and coordination between regional TAGS & regional offices • TAG and office staff should be selected on technical merit not on other criteria • Need the ‘ear’ of health ministers • Limited resources (human and financial) to fulfil tasks

  20. National Immunization Technical Advisory Groups (NITAGS) National Policies and Strategies Prioritize problems and define optimal solutions Implement national programme and monitor impact Have a lot of autonomy

  21. National Immunization Technical Advisory Groups (NITAGS) National Policies and Strategies Prioritize problems and define optimal solutions Implement national programme and monitor impact Have a lot of autonomy • Scarce skilled human resources in many countries, CoIs • Advisory and lack teeth unless empowered by health minister • Need local budgets • Not seen as priority to support EPI in many countries • Important to interpret SAGE recommendations at local level • May not be possible to have meaningful NITAGS in all countries making regional role important

  22. SAGE Challenges • Continuous evaluation & adjustments • Declaration of interests • Heavy work burden for members • Increased credibility and visibility  increased demands and pressure • Processes quite cumbersome • Funding for SAGE core activities • Understaffed and dependent on few excellent staff

  23. Thank you With thanks to Phil Duclos, IVB

  24. WHO vaccine position papers • Position papers = Key reference documents • Available in all official languages • Convergence of other WHO documents (International Travel and Health, Essential Drugs List, …) • Developmental and review process (SAGE, extensive peer review, evidence-base, periodic updating) • Format • Weekly Epidemiological Record • Current structure (Intro, background (Disease epidemiology, the pathogen, disease), info on vaccines (composition, safety, immune response, efficacy and effectiveness, cost effectiveness and any other relevant issue), WHO position on vaccine use) • Additional posting of information on the web: GRADing tables, references, summaries (one pager and PowerPoint presentation)

  25. Pathways for WHO recommendations on vaccine use Industry and other partners SAGE working group Other relevant non immunization related WHO policy recommendation making body Background Paper Secretariat Global Advisory Committee on Vaccine Safety Relevant existing technical advisory committee Expert committee on Biological Standardization WHO Position Paper Country Decision making Recommendations SAGE WHO DG Immunization Practices Advisory Committee Quantitative Immunization and Vaccines related Research Advisory Committee Regional TAGS & NITAGS Regional consultations Input Request for review of evidence

  26. Priority topics for SAGE meetings identified through a survey of SAGE members • Use of vaccines in humanitarian emergencies • Strengthening surveillance networks • Accessibility to affordable vaccines • Communication with vaccine-hesitant populations • Validation of coverage • Use of vaccines in immunocompromised populations

  27. Priority topics for SAGE meetings identified through a survey of SAGE members • Optimizing immunization schedules • Impact of introduction of new vaccines on immunization and health systems • Maternal immunization to enhance the protection of mothers and infants • Involvement of the private sector • Strengthening of national technical advisory groups on immunization (NITAGs).

  28. Challenges • Continuous evaluation & adjustments • Declaration of interests • Heavy work burden for members • Increased credibility and visibility  increased demands and pressure • Processes quite cumbersome • Funding for SAGE core activities • Technical contribution and coordination

  29. Challenges • Importance of regional offices and Advisory Committees in the adaptation of the SAGE recommendations • Weakness of NITAGS • Advisory nature of NITAGS means that recommendations can be ignored • Financial sustainability for countries to implement • Weakness of health services • Vaccine hesitancy

  30. Resources requirements • Staff • Core • Senior health officer • Technical assistant (currently missing) • Administrative assistant • Web assistant, documentalist, clerk, and communication officer (part time) • Specific technical contribution • Resources excluding salaries US$ 700K +

  31. 1 1= move up or down one grade (for example from high to intermediate), 2= move up or down two grades (for example from low to high) 2 Should be commensurate with study design

  32. SAGE: Drivers? Best evidence-based recommendations Impact Usefulness Communication and access Credibility Continuous enhancement of processes as a result of feed-back and external reviews

  33. Declaration of interests • Prior to appointment on committee and updating before each meeting • Discussion with Chair • Public disclosure of DOI and short biography posted on web • Additional guidelines on assessing SAGE members' DOI and framework on how to write public disclosure • Lot of work for secretariat • DOI one element only of credibility and process to avoid conflicts of interest

More Related